Journal of Medicinal Chemistry · 2025 · 10 citations · 22 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignTargeted Cancer TherapyCancer NanotherapyDna Repair PathwaysNanocarrier-based ProdrugsNanoparticle-based ChemotherapyPlatinum CompoundsPlatinum-based AgentsThiol-maleimide CouplingTumor-targeted Drug Delivery
Cisplatin resistance remains a major clinical challenge in cancer therapy, often driven by the upregulation of DNA repair pathways. Here, we present a dual-functional nanotherapeutic system (HFn-NERiP-Pt(IV)) combining a glutathione-responsive PROTAC (NERiP) with a ferritin nanocarrier for targeted ERCC1/XPF degradation and enhanced platinum delivery. NERiP selectively degrades ERCC1/XPF upon release in reductive tumor environments, suppressing nucleotide excision repair and enhancing platinum cytotoxicity. The ferritin nanocage enables tumor-selective codelivery of NERiP and a Pt(IV) prodrug through thiol-maleimide conjugation and pH-triggered release. In vitro and in vivo studies demonstrate effective ERCC1/XPF degradation, increased DNA damage, and significant tumor regression in cisplatin-resistant esophageal squamous cell carcinoma. This rationally designed nanoconjugate integrates targeted protein degradation and chemopotentiation with improved pharmacokinetics, offering a promising strategy to overcome chemoresistance.
22
Platinum Compounds: a New Class of Potent Antitumour Agents
Barnett Rosenberg, Loretta Vancamp, James E. Trosko et al. · Nature · 1969 · 3.9K citations
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
Jung-Hyun Min, Haifeng Yang, Mircea Ivan et al. · Science · 2002 · 770 citations
PHOTACs enable optical control of protein degradation
Martin Reynders, Bryan S. Matsuura, Marleen Bérouti et al. · Science Advances · 2020 · 298 citations · Full text